Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
SONAR committees and Investigators
Presented for research literature review only Zhai J et al
Cagrilintide shows greater potency and a longer half-life (approximately 7 days) than earlier amylin analogs like Pramlintide, which is why its generating attention in the metabolic optimization space
Allison Whitten Pfizer's LITFULO meets primary endpoints in Phase 3 vitiligo trials Pfizer reported topline results from two Phase 3 trials of LITFULO (ritlecitinib) in nonsegmental vitiligo, with both the 50 and 100 milligram once-daily doses meeting co-primary endpoints for facial and total body repigmentation over placebo at Week 52
US$ 21.10
US$ 25.63
US$ 28.89
US$ 28.15
US$ 21.42
US$ 22.31
US$ 25.29
US$ 25.81
